Search - tctmd.com

Displaying 21 - 40 of 52

Sort: Relevancy | Date

The Alleviant No-Implant Interatrial Shunt for HF: The ALLEVIATE HF1 Trial Results

Presentation TVT 2022

The Alleviant No-Implant Interatrial Shunt for HF: The ALLEVIATE HF1 Trial Results

Presenter: Peter S. Fail

June 10, 2022

The Future of Balloon-Expandable TAVR: SAPIEN X4 and the ALLIANCE Trial

Presentation TVT 2022

The Future of Balloon-Expandable TAVR: SAPIEN X4 and the ALLIANCE Trial

Presenter: Tamim M. Nazif

June 08, 2022

Embolic Protection Snags Debris in Nearly All Lower-Risk TAVI Patients

News Daily News

Embolic Protection Snags Debris in Nearly All Lower-Risk TAVI Patients

March 16, 2022

Episode 132: The RIVER Trial

Podcast TCTMD Talking Points

The RIVER Trial

November 10, 2021

William R. Hiatt, Giant of Vascular Medicine, Dies at 70

News Daily News

William R. Hiatt, Giant of Vascular Medicine, Dies at 70

December 11, 2020

Rivaroxaban an Option for Patients with Bioprosthetic Mitral Valves and A-fib

News Conference News AHA 2020

Rivaroxaban an Option for Patients with Bioprosthetic Mitral Valves and A-fib

November 14, 2020

In CAD, No Long-term Safety Signal for Paclitaxel DCBs: Meta-analysis

News Daily News

In CAD, No Long-term Safety Signal for Paclitaxel DCBs: Meta-analysis

March 09, 2020

Nearly 1 Year Later, Endovascular Community Continues to Struggle With Paclitaxel

News Conference News VIVA 2019

Nearly 1 Year Later, Endovascular Community Continues to Struggle With Paclitaxel

November 08, 2019

Acknowledgment of Safety Signal for Paclitaxel Devices in PAD May Mark Sea Change in Controversy

News Conference News CRT 2019

Acknowledgment of Safety Signal for Paclitaxel Devices in PAD May Mark Sea Change in Controversy

March 06, 2019

A Day of Data: Signal of Mortality Increase With Paclitaxel Devices in PAD Continues to Vex

News Daily News

A Day of Data: Signal of Mortality Increase With Paclitaxel Devices in PAD Continues to Vex

March 01, 2019

No Gender Difference in Patency Rates 1 Year After DCB for PAD: ILLUMENATE Substudy

News Conference News VIVA 2018

No Gender Difference in Patency Rates 1 Year After DCB for PAD: ILLUMENATE Substudy

November 13, 2018

Eluvia Gains FDA Approval Just Days After IMPERIAL Results Released

News Conference News TCT 2018

Eluvia Gains FDA Approval Just Days After IMPERIAL Results Released

September 24, 2018

IMPERIAL: Eluvia Tops Zilver PTX in Battle of DES in Femoropopliteal Disease

News Conference News TCT 2018

IMPERIAL: Eluvia Tops Zilver PTX in Battle of DES in Femoropopliteal Disease

September 22, 2018

Debate Over Cerebral Protection in TAVR Fizzles in the Face of Reimbursement Hopes

News Conference News SCAI 2018

Debate Over Cerebral Protection in TAVR Fizzles in the Face of Reimbursement Hopes

April 28, 2018

REAL PTX: Head-to-Head DCB, DES Data in PAD Show Trend Favoring Stenting at 36 Months

News Daily News

REAL PTX: Head-to-Head DCB, DES Data in PAD Show Trend Favoring Stenting at 36 Months

February 11, 2018

ACT I: Women Reap More Long-term Benefits From Carotid Stenting vs CEA

News Conference News VIVA 2017

ACT I: Women Reap More Long-term Benefits From Carotid Stenting vs CEA

September 15, 2017

News Conference News AHA 2015

RIVER-PCI Subanalysis: No Impact of Ranolazine on Quality of Life

November 09, 2015

News Conference News AHA 2015

AHA 2015 Promises Appropriate PCI, Ticagrelor Tolerance, Outcomes With IVUS, and More

November 05, 2015

RIVER-PCI: A Prospective, Double-Blind, Placebo-Controlled Randomized Trial of Ranolazine in Patients With Incomplete Revascularization After Coronary Intervention

Presentation TCT 2015

RIVER-PCI: A Prospective, Double-Blind, Placebo-Controlled Randomized Trial of Ranolazine in Patients With Incomplete Revascularization After Coronary Intervention

Presenter: Sunil V. Rao, Giora Weisz

October 13, 2015

RIVER-PCI: A Prospective, Double-blind, Placebo-Controlled Randomized Trial of Ranolazine in Patients With Incomplete Revascularization After Coronary Intervention

Presentation TCT 2015

RIVER-PCI: A Prospective, Double-blind, Placebo-Controlled Randomized Trial of Ranolazine in Patients With Incomplete Revascularization After Coronary Intervention

Presenter: Giora Weisz

October 13, 2015

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.